The Food and Drug Administration (FDA) in June issued a Drug Safety Communication Update for Actos, warning that patients using Actos (pioglitazone) for a year or longer have a substantially increased risk of bladder cancer.
The update follows on the heels of the FDA’s September 17, 2010, Safety Communication, which revealed that patients taking Actos over several years had an increased risk of bladder cancer. That Safety Communication was based on a planned five-year interim analysis of an ongoing, ten-year study that found as patients’ bladder cancer risks increased with patients’ exposure.
In its latest Communication, the FDA noted a French Study which found a statistically significant increase in the risk of bladder cancer in Actos patients as compared to patients using other diabetic medications. Some European countries have already banned the use of Actos.
Sheller, P.C. is investigating the link between Actos and bladder cancer. If you or someone you know has taken Actos and developed bladder cancer, call 1-800-833-2299.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.